Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

Recruiting now · Phase 4

Conditions studied: Idiopathic Hypersomnia

In brief

Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is awake or asleep.

Key facts

Study ID
NCT05837091
Run by
Mayo Clinic
People needed
30
Starts
2024-02-14
Expected to finish
2027-06-01
Last updated by the study team
2026-05-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.